Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
709 (USA) · Dr. Novak
consented 2014-04-12
AEs
2
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Mild APPLICATION SITE DERMATITIS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-05-08 (study day 27.0); relationship: PROBABLE
mild
assessed
Mild RASH — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-08-02 (study day 113.0); relationship: NONE
Data queries
No data queries.